Abpro Holdings, Inc. Annual Report: A Plain-English Guide

I am breaking down Abpro’s recent performance to help you decide if this company fits your investment goals.

1. What does the company do?

Abpro is a biotech company developing antibody therapies for cancer and eye diseases. Their "TetraBi" platform acts like a modular chassis, allowing them to swap out targeting parts to create different drugs while keeping the same structural backbone.

This year was a turning point. After merging with Atlantic Coastal Acquisition Corp. II in late 2024, Abpro went public. They are currently traded on the "OTC Pink" market under the ticker ABP. Keep in mind that OTC stocks often have lower trading volume and less strict reporting requirements, which can make them riskier for individual investors.

2. Financial performance

Abpro is in the "pre-revenue" stage, meaning they have no products on the market and no sales. For the year ending December 31, 2025, they lost about $48.2 million, primarily due to research and administrative costs.

To fund operations, the company issues more shares. The share count jumped from 2.7 million in 2025 to nearly 5.9 million by early 2026. This creates "dilution," which means your ownership percentage and potential future earnings per share shrink as more shares are created.

3. Major wins and challenges

The FDA cleared their application to test ABP-102 in early 2026. This drug, which targets HER2-positive cancer, is being developed with the firm Celltrion, with human trials expected to begin in 2026.

However, the company faces significant hurdles:

• Financial Survival: Management has noted that they may not be able to continue as a going concern. They lack sufficient cash to fund operations for the next year, and the loss of their Nasdaq listing resulted in the cancellation of a $100 million funding deal.
• Legal Issues: The company is in breach of a contract with AstraZeneca regarding the ABP-201 project, which creates the risk of litigation or the loss of the program.
• Leadership Turnover: There have been significant changes in the C-suite, including the departure of the Chief Medical Officer in 2025 and the appointment of a consultant as acting CEO.

4. The Science: A "Pipeline in a Format" Strategy

The TetraBi platform aims to make drug manufacturing cheaper and faster. Because Abpro relies on trade secrets rather than broad patents for this platform, they face "key-man" risk: if their top scientists leave, the company could lose its competitive edge.

5. Financial health and risks

The company’s finances are fragile. Auditors have identified "material weaknesses" in their internal controls, specifically noting a lack of accounting staff and poor documentation.

Key risks to consider:

• Dilution: Expect further share issuance to fund research, which will continue to dilute your investment.
• Volatility: Trading on the OTC market can lead to extreme price swings and difficulty buying or selling shares.
• Going Concern: Without a new cash infusion, the company faces a high risk of running out of money.
• Early Stage: They have no proven products. Most biotech drugs fail to reach the market, and there is no guarantee any of Abpro’s candidates will succeed.

Final Thought for Investors: Abpro is a high-risk, speculative biotech play. Because they are currently facing a potential cash shortfall, legal disputes, and the challenges of trading on the OTC market, this investment is best suited for those who are comfortable with the possibility of a total loss in exchange for the potential of their early-stage drug pipeline. Always weigh these risks against your personal tolerance for volatility.